Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2003
05/01/2003WO2002090352A3 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
05/01/2003WO2002089835A3 Pharmaceutical dosage form of amorphous nelfinavir mesylate
05/01/2003WO2002083151A3 Compositions and methods for treating an arthritic condition
05/01/2003WO2002081478A3 Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
05/01/2003WO2002079186A3 Aminopiperidine derivatives as modulators of chemokine receptor activity
05/01/2003WO2002078681A3 Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
05/01/2003WO2002078634A3 Methods for using kdop and kdop synthase inhibitors for the treatment of bacterial infection
05/01/2003WO2002076438A3 Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
05/01/2003WO2002074292A3 Hormone replacement therapy
05/01/2003WO2002074287A3 Antibacterial compositions containing of oxapenem-3-carboxylic acids and antibiotics
05/01/2003WO2002072581A3 Pyrazolopyriadine derivatives
05/01/2003WO2002067866A3 Piperazine derivatives as metalloprotease inhibitors
05/01/2003WO2002058685A3 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
05/01/2003WO2002051415A3 Use of sequestrants for treating prion diseases
05/01/2003WO2002051406A9 Methods for inducing apoptosis and inhibiting proliferation in cancer cells
05/01/2003WO2002049633A3 Use of amidoamines to treat or prevent acanthamoeba and fungal infections
05/01/2003WO2002049627A3 Antifungal compositions containing an antibiotic and one or more amidoamines
05/01/2003WO2002048165A3 Antiviral agents for treatment of flaviviridae infections
05/01/2003WO2002048148A3 Pyrazolopyridine derivatives
05/01/2003WO2002046158A9 Piperidine/piperazine-type inhibitors of p38 kinase
05/01/2003WO2002045704A3 Prevention and treatment of tachyphylactic response
05/01/2003WO2002045525A3 Aged companion pet diet
05/01/2003WO2002044113A9 Use of(-) (3-halomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
05/01/2003WO2002043739A3 Dermatological formulations containing clindamycin and a zinc-salt
05/01/2003WO2002042256A3 N-alkylated gaba compounds, processes for their preparation and their use as medicaments
05/01/2003WO2002040056A3 Carrageenan viscoelastics for ocular surgery
05/01/2003WO2002039995A3 Combination therapy for estrogen-dependent disorders
05/01/2003WO2002038600A3 C. elegans genes involved in viability and/or reproduction and uses thereof
05/01/2003WO2002038553A3 Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists
05/01/2003WO2002030409A9 Methods for the treatment of a traumatic central nervous system injury
05/01/2003WO2002027023A3 Genetic determinants for dermal inflammation and immunity
05/01/2003WO2002026224A3 Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
05/01/2003WO2002013873A3 P97-active agent conjugates and their methods of use
05/01/2003WO2002012442A3 Heterocyclic compounds as ligands of the gabaa receptor
05/01/2003WO2002005834A3 Novel uses for thyroid hormones or thyroid hormone-like agonist compounds for treating dermis conditions
05/01/2003WO2002000244A3 Protein mixtures for wound healing
05/01/2003WO2001098346A3 Methods and compositions for the treatment of peripheral artery disease
05/01/2003WO2001066572A3 Polynucleotides isolated from e. coli of nature b2/d+ a-, and uses thereof
05/01/2003US20030084471 Methods and compositions for RNA interference
05/01/2003US20030083642 Devices and methods for the restoration of a spinal disc
05/01/2003US20030083614 For insertion at a vascular site via catheter placement to treat or prevent fibrin-dependent microcirculation disorders; self-expanding; drug-delivery
05/01/2003US20030083609 Device for transdermal electrotransport delivery of fentanyl and sufentanil
05/01/2003US20030083521 Such as 5-phenyl-2,4-pentadienoylhydroxamic acid; for treating cancer, hematopoiesis, and genetic metabolic disorders (cystic fibrosis and adrenoleukodystrophy)
05/01/2003US20030083518 Substituted alcohols useful in treatment of Alzheimer's disease
05/01/2003US20030083509 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
05/01/2003US20030083508 Method for the preparation of citalopram
05/01/2003US20030083504 N- (4-carbamimidoyl-phenyl) -glycine derivatives
05/01/2003US20030083501 Process for preparing paroxetine HCl which limits formation of pink colored compounds
05/01/2003US20030083500 Imidazonaphthyridines
05/01/2003US20030083499 Pyridomorphinans and use thereof
05/01/2003US20030083494 Porphyrins containing multiple carborane cages which selectively accumulate in neoplastic tissue within the irradiation volume; anticancer agents
05/01/2003US20030083493 Eplerenone drug substance having high phase purity
05/01/2003US20030083481 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of prostate cancer
05/01/2003US20030083466 cDNA clone MY1 that encodes a novel human 7-transmembrane receptor
05/01/2003US20030083465 Protein for use in treatment and prevention of angiogenesis
05/01/2003US20030083386 Small molecules used to increase cell death
05/01/2003US20030083385 Such as 1-(5-(2-(5-chloro-2-methoxybenzamido)ethyl)-2-(2-methoxyethoxy) -(phenylsulfonyl)-3-methylthiourea; treating cardiovascular disorders
05/01/2003US20030083384 Formed via chemical reduction and hydrolysis with minimal use of halogenated solvents; comprises use of intermediates such as ethyl 2-benzylideneamino-2-difluoromethyl-4-cyanobutanoate
05/01/2003US20030083382 Orally administered dosage forms of GABA analog prodrugs having reduced toxicity
05/01/2003US20030083381 Comprises 5,6,7-tirnor-4,8-inter-m-phenylene prostaglandin receptor ligand/derivative; side effect reduction
05/01/2003US20030083380 Comprises 2-ketoethanoic acid for cosmetic conditions and dermatologic disorders
05/01/2003US20030083379 Rapidly absorbed liquid compositions
05/01/2003US20030083378 Comprises 4-(6-acetyl-3-(3-((4-acetyl-3-hydroxy-2-propylphenyl)thio)propoxy)-2 -propylphenoxy)butyric acid for its selective leukotriene antagonist activity
05/01/2003US20030083377 Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor
05/01/2003US20030083375 Such as (5Z,13E)-(9S,11S,15R)-9,15-dihydroxy-11-fluoro-15-(2-indanyl)-16,17,18,19,20-pentanonr-5,13-prostadienoic acid isopropyl ester; prostaglandins for treatment of ocular hyperemia, macular edema, iris hyperpigmentation/melanogenesis
05/01/2003US20030083374 NAALADase inhibitors useful as pharmaceutical compounds and compositions
05/01/2003US20030083372 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain
05/01/2003US20030083370 Administering 5-amino-2,2-dimethyl-6-(3'-(R,S)amino-4'-hydroxy-butan-1-one)-2,3-dihydro-4H-1-benzopyran-4-one (FC101) for treatment of neovascularization and cellular proliferation; antitumor agents; veterinary medicine
05/01/2003US20030083369 Pyranocoumarin compounds as a novel pharmacophore with anti-TB activity
05/01/2003US20030083368 Cancer cell implantation inhibitors
05/01/2003US20030083367 Diesterifying paclitaxel with hexanoic acid; antitumor agents
05/01/2003US20030083366 Combination chemotherapy
05/01/2003US20030083365 Such as 1-(3-(((3,4-dihydro-2H-1-benzopyran-2-yl)methyl) amino)-propyl)tetrahydro-2(1H)-pyrimidinone for treatment of irritable bowel syndrome and other gastrointestinal disorders
05/01/2003US20030083363 Prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
05/01/2003US20030083360 Compaction process for manufacture of sodium phenytoin dosage form
05/01/2003US20030083357 Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
05/01/2003US20030083356 Statine derivatives for the treatment of Alzheimer's disease
05/01/2003US20030083354 Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
05/01/2003US20030083353 Beta-secretase inhibitors
05/01/2003US20030083351 Antihypoxic agents
05/01/2003US20030083349 Antimalaria agents
05/01/2003US20030083348 Farnesyl transferase inhibitors
05/01/2003US20030083347 Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
05/01/2003US20030083346 Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
05/01/2003US20030083345 Method of treatment and/or prevention of brain, spinal or nerve injury
05/01/2003US20030083344 Tryptase inhibitors
05/01/2003US20030083343 Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
05/01/2003US20030083342 Combination of organic compounds
05/01/2003US20030083341 2,3,5-Substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
05/01/2003US20030083339 Using antagonists of the Angiotensin II type 2 receptor (AT2 receptor) for example candesartan cilexetil; combination treatment with an ACE inhibitor (angiotensin converting enzyme=ACE); drug screening assays
05/01/2003US20030083338 A nefazodonoid and a serotonin reuptake inhibitor (SRI); dosage forms; treating depression
05/01/2003US20030083337 Optically active 3-[(2-piperazinylphenyl)methyl]-1-[4-(trifluoromethyl)phenyl]-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
05/01/2003US20030083336 Dopamine D4 receptor ligands; treating psychosis, schizophrenia and affective disorders
05/01/2003US20030083335 CCR1 receptor antagonists; inhibitors of MIP-1 alpha (CCL3) binding to its receptor CCR1 found on inflammatory and immunomodulatory cells; macrophage inflammatory protein (MIP)
05/01/2003US20030083333 1,4-Disubstituted benzo-fused compounds
05/01/2003US20030083332 N-heterocyclic derivatives as NOS inhibitors
05/01/2003US20030083330 Pharmaceutically active morpholinol
05/01/2003US20030083326 Dihydroxyphenyl derivatives for hepatoprotection and treatment of liver diseases
05/01/2003US20030083325 Serotonin antagonists
05/01/2003US20030083324 Photosensitizing ointment
1 ... 5484 5485 5486 5487 5488 5489 5490 5491 5492 5493 5494 5495 5496 5497 5498 5499 5500 5501 5502 5503 5504 ... 7860